Current treatment of myeloproliferative neoplasias: three scenarios

Med Clin (Barc). 2020 Feb 28;154(4):131-133. doi: 10.1016/j.medcli.2019.05.009. Epub 2019 Jul 24.
[Article in English, Spanish]
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Myeloproliferative Disorders / therapy*
  • Niacinamide / analogs & derivatives
  • Niacinamide / therapeutic use
  • Nitriles
  • Polycythemia Vera / drug therapy
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrazoles / therapeutic use
  • Pyrimidines
  • Recurrence
  • Remission Induction
  • Thrombocythemia, Essential / drug therapy
  • Time Factors
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • asciminib
  • Niacinamide
  • ruxolitinib
  • Imatinib Mesylate